Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Supports End-To-End Management Of Trials Undergoing Combined Reviews

Executive Summary

Ongoing efforts by the UK to deliver a single decision on the ethical and regulatory approval of new clinical trial applications have reached a major milestone ahead of the 2022 mandatory deadline. 

You may also be interested in...



Combined Trial Reviews To Become The Norm In UK From 2022

Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.

New Big Data Curriculum On The Cards For EU Regulators

The European Medicines Agency is inviting feedback from organizations interested in delivering a training program to the members of the European medicines regulatory network to improve their big data analysis and assessment skills.

New UK System Will Check Trial Sponsors Report Study Results

The UK has started monitoring whether clinical trial sponsors are fulfilling responsibilities to make their research open and transparent.

Topics

UsernamePublicRestriction

Register

PS144886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel